Two biotechs and a Chinese real estate company entered the public market, accompanied by two SPACs. All three companies priced at the bottom of the range, while both SPACs upsized their unit offerings. Seven Chinese companies filed for US IPOs, along with two SPACs that submitted initial filings.
Chinese real estate platform Fangdd Network Group (DUO) downsized its ADS offering to raise $78 million (25% insider) at a $1.1 billion market cap. The company has demonstrated profitability and accelerating growth in the 1H19, but high payouts to third-party agents have weighed on its gross margin, which has hovered at 21%. While it didn’t perform as poorly as recent Chinese IPOs, Fangdd did break issue intraday but finished flat at its IPO price.
Oyster Point Pharma (OYST), a Phase 3 biotech developing a nasal spray formulation for dry eye disease, raised $80 million at a $363 million market cap. Phase 1 immunology biotech RAPT Therapeutics (RAPT) raised $36 million, 44% from insiders, at a $262 million market cap. The company revived its IPO plans after postponing its $75 million deal in August.
The two SPACs that went public this week upsized their unit offerings. Edward and Jonathan Cohen’s second SPAC Osprey Technology Acquisition (SFTW.U) raised $275 million to acquire a tech business, and fintech SPAC FinServ Acquisition (FSRVU) raised $220 million.
In other news, Virgin Galactic (SPCE), the first publicly listed human-spaceflight company, began trading under its new name and ticker following its merger with publicly-traded SPAC Social Capital Hedosophia, which IPO’d in 2017. The company’s shares finished the week 4% below the $10 benchmark.
In non-US IPO news, nearly four years after disclosing intentions to go public, Saudi Aramco is expected to launch its IPO on November 3. Saudi’s crown prince is seeking to value the company at $2.0 trillion in what could be the world’s largest IPO.
| 5 IPOs During the Week of October 28th, 2019 | |||||
|---|---|---|---|---|---|
| Issuer Business |
Deal Size |
Market Cap at IPO |
Price vs. Midpoint |
First Day Return |
Return at 11/01 |
| Oyster Point Pharma (OYST) | $80M | $363M | -6% | +17% | +12% |
| Phase 3 biotech developing a nasal spray formulation for dry eye disease. | |||||
| RAPT Therapeutics (RAPT) | $36M | $262M | -20% | +8% | +6% |
| Phase 1 biotech developing therapies for cancer and inflammatory diseases. | |||||
| FinServ Acquisition (FSRVU) | $220M | $276M | 0% | +1% | +1% |
| Blank check company targeting the fintech industry led by finance veterans. | |||||
| Fangdd Network Group (DUO) | $78M | $1,087M | -7% | +0% | +0% |
| Chinese online real estate marketplace. | |||||
| Osprey Technology Acq. (SFTW.U) | $275M | $338M | 0% | n/a | +0% |
| Second blank check company led by Edward and Jonathan Cohen targeting the tech industry. | |||||
Sign up for a free trial of our premium platform, IPO Pro. Follow us on Twitter (@IPOtweet) and register for our updates on the IPO market.
Despite poor recent performances from Chinese issuers, seven have filed for US IPOs. Canaan (CAN), a leading maker of cryptocurrency mining equipment, filed to raise $400 million. Apartment sub-leaser Phoenix Tree Holding (DNK), operating under the name Danke Apartment, filed for an estimated $300 million US IPO.
Podcast platform LIZHI (LIZI), Phase 3 immunotherapy biotech I-Mab Biopharma (IMAB), used car financer Meili Auto Holdings (ML), and drone maker EHang Holdings (EH) all filed to raise $100 million. AnPac Bio-Medical Science (ANPC), which provides multi-cance screening tests, filed to raise $22 million.
| 9 Filings During the Week of October 28th, 2019 | |||
|---|---|---|---|
| Issuer Business |
Deal Size |
Sector | Lead Underwriter |
| Alussa Energy Acquisition (ALUSU) | $225M | SPAC | BTIG |
| Blank check company targeting the energy sector. | |||
| AnPac Bio-Medical Science (ANPC) | $22M | Health Care | WestPark Capital |
| Chinese provider of multi-cancer screening tests. | |||
| CHP Merger Corp. (CHPMU) | $250M | SPAC | JP Morgan |
| Blank check company led by a team from Concord Health Partners targeting the healthcare industry. | |||
| EHang (EH) | $100M | Consumer Discretionary | Morgan Stanley |
| Chinese developer of drones for recreational and commercial uses. | |||
| Meili Auto Holdings (ML) | $100M | Financials | UBS |
| Facilitates used car loans for prime borrowers in China. | |||
| I-Mab Biopharma (IMAB) | $100M | Health Care | Jefferies |
| Phase 3 biotech developing antibodies for cancer and autoimmune diseases. | |||
| Canaan (CAN) | $400M | Technology | Credit Suisse |
| Leading maker of cryptocurrency mining equipment. | |||
| LIZHI (LIZI) | $100M | Technology | Credit Suisse |
| Chinese interactive podcast platform. | |||
| Phoenix Tree Holdings (DNK) | $300M | Real Estate | Citi |
| Renovates and sub-leases apartments in Chinese cities. | |||
Sign up for a free trial of our premium platform, IPO Pro. Follow us on Twitter (@IPOtweet) and register for our updates on the IPO market.
IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 10/31/19, the Renaissance IPO Index was up 27.7% year-to-date, while the S&P 500 had a gain of 21.2%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Spotify (SPOT) and Roku (ROKU). The Renaissance International IPO Index was up 18.5% year-to-date, while the ACWX was up 15.1%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Meituan-Dianping and SoftBank.
